U.S. Markets closed

Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues

Zacks Equity Research

Earnings of Other MedTech Majors at a Glance

Some better-ranked companies, which posted solid results this earnings season, are Edwards Lifesciences (EW), Thermo Fisher Scientific Inc. (TMO) and ResMed Inc. (RMD), each carrying a Zacks Rank #2 (Buy) You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.

Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the consensus estimate by 2.1%. Revenues of $6.27 billion outpaced the consensus estimate by 1.3%.

ResMed reported fiscal first-quarter 2020 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Becton, Dickinson and Company (BDX), also known as BD, reported fourth-quarter fiscal 2019 earnings per share (EPS) of $3.31, which beat the Zacks Consensus Estimate by a penny. The bottom line also improved 13% on a year-over-year basis and rose 12.3% at constant currency (cc).

The Zacks Rank #4 (Sell) company raked in revenues of $4.58 billion, surpassing the Zacks Consensus Estimate of $4.57 billion. The reported figure increased 4.1% from the year-ago quarter. At cc, revenues rose 6.2%.

FY19 at a Glance

On a full-year basis, BD’s revenues increased 8.2% to $17.29 billion, beating the Zacks Consensus Estimate of $17.27 billion. Adjusted EPS was $11.68, up 6.1%. The metric was in line with the Zacks Consensus Estimate.

BD reports through three major segments — BD Medical, BD Life Sciences and BD Interventional.

BD Medical sales were $9.06 billion (52.4% of net sales), BD Life Sciences sales totaled $4.30 billion (24.9%) and BD Interventional sales were $3.93 billion (21.9%).

Becton, Dickinson and Company BDX, also known as BD, reported fourth-quarter fiscal 2019 earnings per share (EPS) of $3.31, which beat the Zacks Consensus Estimate by a penny. The bottom line also improved 13% on a year-over-year basis and rose 12.3% at constant currency (cc).

The Zacks Rank #4 (Sell) company raked in revenues of $4.58 billion, surpassing the Zacks Consensus Estimate of $4.57 billion. The reported figure increased 4.1% from the year-ago quarter. At cc, revenues rose 6.2%.

 

FY19 at a Glance

 

On a full-year basis, BD’s revenues increased 8.2% to $17.29 billion, beating the Zacks Consensus Estimate of $17.27 billion. Adjusted EPS was $11.68, up 6.1%. The metric was in line with the Zacks Consensus Estimate.

 

BD reports through three major segments — BD Medical, BD Life Sciences and BD Interventional.

 

BD Medical sales were $9.06 billion (52.4% of net sales), BD Life Sciences sales totaled $4.30 billion (24.9%) and BD Interventional sales were $3.93 billion (21.9%).

Becton, Dickinson and Company Price, Consensus and EPS Surprise

 

Becton, Dickinson and Company Price, Consensus and EPS Surprise

Becton, Dickinson and Company price-consensus-eps-surprise-chart | Becton, Dickinson and Company Quote

Segment Details

 

BD Medical

 

In the quarter under review, the company reported worldwide revenues of $2.44 billion, up 3.9% from the year-ago quarter and 5.3% at cc. Per management, the segment's results were driven by performance in the Medication Management Solutions, Medication Delivery Solutions and Pharmaceutical Systems units.

 

BD Life Sciences

 

Worldwide revenues in the segment totaled $1.13 billion, up 2.3% year over year and 6.9% at cc. Per management, the upside was driven by solid performance in the Diagnostic Systems and Biosciences units.

 

BD Interventional

 

This segment generated worldwide revenues of $1.01 billion, up 6.9% from the year-ago quarter. At cc, revenues grew 7.7% on strong performance by the Urology and Critical Care and Surgery sub-units.

 

Geographic Results

 

US

 

In the fiscal fourth quarter, revenues in the United States improved 4.6% to $2.56 billion. Revenues grew 4.9% at cc. Per management, growth in the United States was driven by good performance by the BD Medical, BD Life Sciences and the Surgery and Urology and Critical Care units within the BD Interventional segment.

 

International

 

Revenues outside the United States grossed $2.02 billion, up 3.5% from the year-ago quarter. At cc, the segment grew 7.9%. Per management, international revenue growth in the fourth quarter was strong in APAC and EMEA.

 

Margin Analysis

 

In the quarter, gross profit amounted to $2.27 billion, up 8.3% from the prior-year quarter tally. Gross margin was 49.4%, up 190 bps from the prior-year quarter.

 

Operating income in the quarter grossed $111 million, down significantly from the year-ago quarter’s figure of $576 million. As a percentage of revenues, operating margin in the quarter was 2.4%, significantly down from year-ago quarter’s 13.1%.

 

Adjusted operating income amounted to $902 million, up 26.2% from the year-ago figure.

 

Guidance

 

The company expects fiscal 2020 revenues to increase 4-4.5% year over year and 5-5.5% at cc. The Zacks Consensus Estimate is pegged at $18.13 billion.

 

Adjusted EPS is expected between $12.50 and $12.65, indicating growth of 7-8.5% from fiscal 2019. At cc, growth is expected between 9.5% and 11%. The Zacks Consensus Estimate for the same stands at $12.92, higher than the guided range.

 

Wrapping Up

 

BD exited the fiscal fourth quarter on a strong note. Solid performance by the core BD Medical and Interventional segments instills optimism in the stock. Domestic revenues increased year over year in the quarter under review, driven by segmental strength. Growth in Europe and APAC is another positive. Expansion in gross margin is also encouraging. BD has issued a solid guidance for fiscal 2020.

 

Meanwhile, a drop in operating margin raises concern. Management expects unfavorable foreign currency to partially mar BD’s bottom line in fiscal 2020. Competition in the MedTech space is stiff.

 

Earnings of Other MedTech Majors at a Glance

 

Some better-ranked companies, which posted solid results this earnings season, are Edwards Lifesciences EW, Thermo Fisher Scientific Inc. TMO and ResMed Inc. RMD, each carrying a Zacks Rank #2 (Buy) You can see  the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

 

Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.

 

Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the consensus estimate by 2.1%. Revenues of $6.27 billion outpaced the consensus estimate by 1.3%.

 

ResMed reported fiscal first-quarter 2020 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.

 

More Stock News: This Is Bigger than the iPhone!

 

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

 

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
 
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
 
ResMed Inc. (RMD) : Free Stock Analysis Report
 
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.